Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000823072 | SCV000963913 | likely pathogenic | Ehlers-Danlos syndrome, type 4 | 2018-08-25 | criteria provided, single submitter | clinical testing | In summary, this variant is a novel deletion affecting  residue that is known to be critical for normal protein structure, stability and function. This type of change is also highly enriched in affected individuals and expected to be pathogenic. However, without additional functional and/or genetic data, this variant has been classified as Likely Pathogenic. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants at these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). This variant, c.2067_2072delAGGGGC, results in the deletion of 2 amino acids of the COL3A1 protein (p.Gly690_Ala691del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with COL3A1-related disease. |